Cooperative Agreement UG3CA290286
Award Date
5/15/24
Completion Date
4/30/26
Dollars Obligated
$2M
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Cooperative Agreement
Place of Performance
Seattle, WA 98195, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $629,068 Cooperative Agreement under the Cancer Cause and Prevention Research program (CFDA 93.393) to Albert Einstein College of Medicine to conduct an implementation science study on integrated human papillomavirus (HPV) self-sampling for cervical cancer screening in HIV care centers in Ethiopia. The project aims to leverage the Project ECHO model to promote experience-sharing between hospitals and provide technical assistance to improve the...
The National Cancer Institute (NCI) awarded a $643,363 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to Tulane University. The project, titled "A Hybrid Type III Effectiveness-Implementation, Pragmatic Intervention Trial for Cervical Cancer Screen and Treat in Mozambique," will test implementation best practices for deploying a screen and treat approach to cervical cancer screening utilizing self-collected HPV DNA testing within HIV care and...
This $635,035 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund the "Self-Sampling to Optimize Anal Lesion Outcomes (SOLO)" study. The objective is to use a randomized controlled trial to test the effect of self-sampling versus healthcare provider-sampling on attendance at cytology and high-resolution anoscopy (HRA) appointments for sexual and gender minority (SGM) individuals, with a focus on...
This Cooperative Agreement award, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), funds the development and evaluation of a novel, low-cost, rapid, and point-of-care HPV DNA test for cervical cancer screening in Mozambique. The key objectives are to: 1) Adapt an extraction-free, multiplexed, isothermal nucleic acid amplification technology onto an integrated nucleic acid amplification and lateral flow detection platform called NATFLOW, resulting...
This federal Cooperative Agreement award, totaling $706,365.00, was issued by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The award aims to implement the World Health Organization-endorsed "screen, triage, and treat" (ISTAR) approach for cervical cancer screening among women living with HIV in La Romana, Dominican Republic. The project seeks to address barriers to adoption, integration, and sustainability of evidence-based...
The U.S. National Cancer Institute (NCI) has awarded a $1,245,116 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to Emory University in Atlanta, Georgia, to enhance cervical cancer screening and treatment services for women living with HIV in Kenya. The project, titled "ENHANCING CERVICAL CANCER SCREENING AND TREATMENT IN WOMEN LIVING WITH HIV IN KENYA (ENHANCE LINKAGE)," aims to employ rigorous implementation science methods to adapt and test strategies...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, totaling $1,288,122, aims to identify multi-level factors associated with HPV vaccine uptake in Kenya and Malawi. The key products and services to be delivered include: Primary and secondary data collection on policy, systems, community, and individual-level factors impacting HPV vaccine uptake in Kenya and Malawi. This includes qualitative interviews...
This National Cancer Institute (NCI) Project Grant under the Cancer Cause and Prevention Research federal grant program (CFDA 93.393) will fund the "Development of Systems and Education for Cervical Cancer Prevention (DOSE-CC)" project at Boston Medical Center Corporation. The $753,446 grant, awarded on May 1, 2025, aims to adapt and validate an intervention to improve cervical cancer screening and follow-up in three diverse, underserved populations: urban inner city Blacks/Haitians in...
The National Cancer Institute (NCI) has awarded a $1,853,375 Cooperative Agreement grant under the federal Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Utah. The project, titled "Population Health Management Approaches to Increase Lung Cancer Screening in Community Health Centers", aims to increase the reach and equity of lung cancer screening among underserved populations. The two-phase, sequential multiple assignment randomized trial (SMART) will...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $368,070 to conduct research to identify and address barriers in the cervical cancer treatment cascade among women with HIV in South Africa. The research aims to investigate factors that negatively impact follow-up appointment attendance and engagement with necessary cervical cancer treatment for women with HIV, in order to develop a tailored intervention to improve...